# breast cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 30905
- Completion tokens: 11643
- Reasoning tokens: 0
- Total tokens: 42548
- API requests reported: 2
- Elapsed seconds: 138.679
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: OpenAI

---
## Data-quality and evidentiary note

The uploaded results are statistically strong within the analyzed cohort: all **100 unique genes** have **P≤0.05 and FDR≤0.05**, with **52 risk-associated genes (HR>1)** and **48 protective-associated genes (HR<1)**. However, this pattern is technically unusual because significance is extremely broad and uniform, while the HRs are relatively modest, approximately **1.183–1.261 for risk-associated genes** and **0.793–0.838 for protective-associated genes**. The ledger also reports **106 retained rows for 100 unique genes**, including **six duplicated gene/probe rows**.

Accordingly, the within-cohort associations should be treated as the primary evidence, but possible effects of sample size, correlated predictors, probe duplication, model specification, batch structure, or unaccounted clinical covariates should be investigated. **External statistical validation was not performed**: no independent-cohort HR, P value, FDR, or concordant survival estimate was supplied. The pathway, network, tissue, and literature records below therefore provide biological context, not replication.

## 1. Overall biological interpretation

The prognostic pattern is most coherently interpreted as the coexistence of:

1. A broad **cell-division and mitotic machinery program associated with poorer OS**, represented by PKMYT1, RACGAP1, KIF20A, CDCA5, TPX2, KIF4A, UBE2C, CDC20, AURKA, NUSAP1, PRC1, and related genes.
2. A **tumor-cell growth, RNA/protein regulation, signaling, and metabolic-stress program** involving LARP1, STIP1, GSK3B, ATP2A2, CPT1A, GPI, YTHDF1, and others, also risk-associated.
3. A protective-associated signal involving **immune and antigen-presenting cell markers**, including FCER1A, CD1C, CD1E, FLT3, KLRB1, JCHAIN, and IL27RA.
4. A protective-associated **stromal, extracellular-matrix, epithelial-organization, and differentiation signature**, including OGN, COL14A1, MFAP4, LAMA2, ADAMTS8, RELN, COL17A1, CLDN11, TP63, and IGF1.

Thus, the results may reflect both tumor-intrinsic aggressiveness and favorable immune/stromal composition. The opposite directions do not necessarily represent a single linear pathway: some protective genes may be markers of nonmalignant cell populations rather than protective tumor-cell mechanisms.

## 2. Core biological programs

### Program 1: Mitotic progression, chromosome segregation, and cell-cycle activity

- **Association:** Risk-associated with OS.
- **Supporting genes:** PKMYT1 **HR=1.2437685**, RACGAP1 **HR=1.223506**, KIF20A **HR=1.2180492**, CDCA5 **HR=1.2179013**, TPX2 **HR=1.2017253**, KIF4A **HR=1.1985808**, UBE2C **HR=1.2100353**, CDC20 **HR=1.1912581**, AURKA **HR=1.1885146**, NUSAP1 **HR=1.1942371**, PRC1 **HR=1.1859845**, and ZWINT **HR=1.1906277**.
- **Relevant pathway terms:** **KEGG Cell cycle**; GO **Positive Regulation of Mitotic Nuclear Division (GO:0045840)**; related mitotic spindle, chromosome segregation, and ubiquitin-mediated cell-cycle control processes.
- **Interpretation:** Multiple independent components of mitotic entry, spindle function, cytokinesis, kinetochore activity, and anaphase regulation show the same risk direction. The external network records also connect selected genes to PLK1, TPX2, ANAPC2, BUB1B, and DLGAP5. This is a coherent program rather than an inference based on one canonical proliferation gene.
- **Evidence strength:** **Strong within-cohort program-level evidence**, supported by pathway annotation and network convergence.
- **Limitations:** The supplied pathway records were retrieved annotations and were **not newly recomputed enrichment statistics**. Proliferation can be a general marker of high-grade disease, stage, subtype, or treatment resistance and does not establish that any individual mitotic protein causes poor survival.

### Program 2: Growth control, translational regulation, and cellular stress/metabolism

- **Association:** Predominantly risk-associated.
- **Supporting genes:** LARP1 **HR=1.2611983**, STIP1 **HR=1.2368966**, GSK3B **HR=1.2271421**, ATP2A2 **HR=1.2378678**, CPT1A **HR=1.1962357**, YTHDF1 **HR=1.1923944**, GPI **HR=1.1924932**, TRIB3 **HR=1.1914433**, and HACD3 **HR=1.1970276**.
- **Relevant pathway terms:** GSK3B is annotated in **ErbB signaling**, **chemokine signaling**, and **cell cycle**; LARP1 and YTHDF1 are consistent with post-transcriptional and translational control; CPT1A and GPI support lipid oxidation and glycolytic/metabolic activity. No formal pathway-level P value for this specific program was supplied.
- **Interpretation:** The combined pattern is compatible with tumors characterized by increased biosynthetic demand, altered energy utilization, proteostatic or endoplasmic-reticulum stress, and growth-supporting signaling. The risk association of LARP1 is the strongest displayed HR, while STIP1 and GSK3B provide additional signaling and stress-related context.
- **Evidence strength:** **Moderate supported hypothesis**: coherent functional annotations and multiple risk-associated genes, but less internally specific than the mitotic program.
- **Limitations:** These processes are broad and may largely track proliferation. CPT1A, GPI, ATP2A2, and GSK3B do not prove a common metabolic mechanism in the tumor cells. The cited literature record for STIP1 (PMID **37488801**) discusses prognosis and immune infiltration in a pan-cancer context, but does not constitute independent validation of this breast-cancer cohort.

### Program 3: Immune-cell and antigen-presentation-associated composition

- **Association:** Protective-associated with OS.
- **Supporting genes:** FCER1A **HR=0.7932319**, JCHAIN **HR=0.80290118**, STAT5A **HR=0.80627148**, CD1C **HR=0.81422548**, CD1E **HR=0.82361278**, FLT3 **HR=0.81703284**, KLRB1 **HR=0.82162453**, IL27RA **HR=0.82546531**, and STAT5B **HR=0.83716163**.
- **Relevant pathway terms:** Immune-cell differentiation, antigen receptor/antigen-presentation biology, cytokine signaling, and **chemokine signaling** are the most appropriate contextual categories. A single specific GO or KEGG term cannot be assigned confidently from the supplied records alone.
- **Interpretation:** The coordinated protective direction of dendritic/antigen-presenting markers such as FCER1A, CD1C, CD1E, and FLT3, together with KLRB1 and cytokine-response genes, is compatible with greater immune infiltration or a more active immune microenvironment being associated with longer OS.
- **Evidence strength:** **Strong association-level evidence for an immune-composition hypothesis**, because several biologically related markers move together.
- **Limitations:** Bulk tumor RNA cannot distinguish immune abundance from tumor-cell expression. This signature may reflect immune infiltration, tumor purity, treatment exposure, or subtype composition rather than an intrinsically protective immune mechanism. Literature support is contextual; no independent survival statistic was supplied.

### Program 4: Extracellular matrix, stromal organization, and tissue architecture

- **Association:** Protective-associated with OS.
- **Supporting genes:** OGN **HR=0.80743973**, COL14A1 **HR=0.82355765**, MFAP4 **HR=0.83417958**, LAMA2 **HR=0.83003966**, ADAMTS8 **HR=0.7928718**, RELN **HR=0.79635886**, PDGFRA **HR=0.83760447**, RBP7 **HR=0.83174472**, and LAMA2-associated matrix organization.
- **Relevant pathway terms:** Extracellular matrix organization, collagen-containing extracellular matrix, cell–matrix adhesion, and stromal organization; the supplied GO recurrence includes **extracellular region**.
- **Interpretation:** These genes collectively indicate matrix and stromal architecture rather than a single isolated ECM marker. Their protective direction may mark a less dedifferentiated or less invasive tissue state, but it may also reflect the abundance of fibroblast, vascular, adipose, or other stromal compartments.
- **Evidence strength:** **Moderate supported hypothesis**, based on coordinated direction and tissue-relevant annotations.
- **Limitations:** ECM expression in bulk tumor is particularly vulnerable to cellular-composition confounding. Matrix abundance is not equivalent to a biologically favorable matrix; some activated fibroblast states can promote tumor progression. The current data do not resolve these alternatives.

### Program 5: Epithelial differentiation, adhesion, and tissue identity

- **Association:** Predominantly protective-associated, although not uniform.
- **Supporting genes:** COL17A1 **HR=0.79759519**, TP63 **HR=0.81019607**, CLDN11 **HR=0.81928027**, PCDH18 **HR=0.82465423**, SPRY2 **HR=0.80649852**, IGF1 **HR=0.80347674**, and CBX7 **HR=0.8307581**. GRHL2 is an exception with risk association, **HR=1.2174018**.
- **Relevant pathway terms:** Epithelial cell differentiation, cell–cell adhesion, tight-junction/epithelial organization, and growth-factor signaling.
- **Interpretation:** The protective-associated genes are compatible with preserved epithelial or tissue-identity features and reduced invasive behavior. However, GRHL2 shows the opposite direction, emphasizing that this is not a uniformly defined epithelial differentiation axis.
- **Evidence strength:** **Exploratory to moderate**, because the directionally consistent subset is biologically plausible but partly heterogeneous.
- **Limitations:** Epithelial markers can be confounded by tumor purity and histologic subtype. The opposite GRHL2 result and the lack of direct expression-level or subtype information prevent a definitive epithelial-state interpretation.

## 3. Key genes and interaction modules

The following candidates are prioritized for biological coherence, not solely by HR magnitude.

| Candidate/module | Current result and role | Relationship type and interpretation |
|---|---|---|
| **PKMYT1–mitotic kinase module** | PKMYT1 is risk-associated, **HR=1.2437685, FDR=9.7437879e-10**; fits mitotic entry and cell-cycle control. | Pathway co-membership with the mitotic program; any direct interaction with the other selected genes is **not established by the supplied evidence**. |
| **AURKA–TPX2 spindle module** | AURKA **HR=1.1885146** and TPX2 **HR=1.2017253**, both risk-associated. | STRING reports network associations involving TPX2, AURKA, KIF4A, NUSAP1, and PRC1. This supports a **functional/network relationship**, not necessarily a direct physical interaction for every pair. |
| **CDC20–UBE2C–UBE2S module** | CDC20 **HR=1.1912581**, UBE2C **HR=1.2100353**, and UBE2S **HR=1.1841829**, all risk-associated. | Co-membership in ubiquitin-dependent cell-cycle control; the STRING/ANAPC2 records support network association. Direct physical binding should not be inferred without pair-specific biochemical evidence. |
| **RACGAP1–KIF20A cytokinesis module** | RACGAP1 **HR=1.223506** and KIF20A **HR=1.2180492**, risk-associated. | Shared cytokinesis and spindle-related biology; primarily **pathway co-membership and functional association**. |
| **LARP1–STIP1 growth/stress pair** | LARP1 **HR=1.2611983** and STIP1 **HR=1.2368966**, risk-associated. | Putative convergence on translational control, chaperone/stress responses, and tumor growth; **indirect or putative relationship**, not a demonstrated direct interaction here. |
| **GSK3B signaling node** | GSK3B is risk-associated, **HR=1.2271421**. | STRING records high-confidence associations with AXIN1/2, APC, CTNNB1, DVL1, and related Wnt components. These are **database-supported protein/network associations**; the survival result does not show that Wnt signaling is causally activated. |
| **CPT1A–metabolic adaptation signal** | CPT1A is risk-associated, **HR=1.1962357**. | Functional association with fatty-acid oxidation is plausible; a direct relationship with the mitotic genes is **indirect/putative** and may simply reflect aggressive tumor biology. |
| **FCER1A–CD1C–CD1E–FLT3 immune module** | FCER1A **HR=0.7932319**, CD1C **HR=0.81422548**, CD1E **HR=0.82361278**, and FLT3 **HR=0.81703284**, all protective-associated. | Immune-cell lineage and antigen-presentation **co-membership**; likely reflects coordinated cell abundance or state. It is not evidence of direct physical interaction among all four genes. |
| **STAT5A–STAT5B cytokine-response module** | STAT5A **HR=0.80627148** and STAT5B **HR=0.83716163**, protective-associated. | Regulatory/pathway co-membership in cytokine signaling. The network records also include a STAT3-centered association involving FLT3, LEPR, STAT5A, and STAT5B; this is not proof of direct STAT5A–STAT5B binding in the tumor samples. |
| **OGN–COL14A1–MFAP4 matrix module** | OGN **HR=0.80743973**, COL14A1 **HR=0.82355765**, and MFAP4 **HR=0.83417958**, protective-associated. | Extracellular-matrix **co-membership and likely co-expression in stromal compartments**; direct protein interactions are not established by the supplied records. |

## 4. Validation priorities

### 1. Proliferation/mitotic activity as a prognostic mechanism  
**Classification:** Mechanistic hypothesis

- **Why prioritize it:** It is the most internally coherent risk-associated program, spanning mitotic kinases, spindle proteins, chromosome segregation, and ubiquitin-mediated cell-cycle control.
- **Current evidence:** Multiple genes have highly significant risk associations, including PKMYT1, RACGAP1, KIF20A, TPX2, UBE2C, CDC20, AURKA, and PRC1. The retrieved KEGG Cell cycle and GO mitotic annotations support biological plausibility.
- **External support or conflict:** STRING network records connect several genes to PLK1, TPX2, ANAPC2, BUB1B, and DLGAP5. These are contextual network data, not an independent survival analysis. No conflicting external statistical result was supplied.
- **Next step:** Test a prespecified proliferation score in an independent breast-cancer cohort, adjusted for stage, grade, molecular subtype, treatment, and age; then assess protein-level activity by Ki-67, phospho-AURKA/PLK1, and mitotic indices.
- **Conclusion status:** **Supported hypothesis**, not established causality.

### 2. Composite prognostic biomarker combining tumor proliferation and immune/stromal composition  
**Classification:** Biomarker

- **Why prioritize it:** Risk-associated proliferation and protective-associated immune/ECM signals may provide complementary information, but their value must be demonstrated jointly rather than inferred gene by gene.
- **Current evidence:** The cohort contains coordinated risk genes in cell-cycle programs and coordinated protective markers such as FCER1A, CD1C, CD1E, FLT3, OGN, COL14A1, and MFAP4.
- **External support or conflict:** PROS1 is protective-associated in this dataset, **HR=0.83621827**, and a supplied breast-cancer publication reports PROS1 as a prognostic biomarker associated with immune infiltration (PMID **37827342**). This is biologically concordant but not an independent statistic for the present cohort. No complete external model performance was supplied.
- **Next step:** Build and lock a parsimonious score in a training cohort, validate it in independent cohorts using C-index, time-dependent AUC, calibration, and multivariable Cox models, and compare it with standard clinicopathologic variables.
- **Conclusion status:** **Exploratory hypothesis** until externally validated.

### 3. Immune-marker signal versus tumor-purity/cell-composition confounding  
**Classification:** Confounding or composition check

- **Why prioritize it:** The protective direction of dendritic, lymphoid, and antigen-presentation markers may reflect greater immune-cell abundance rather than protective tumor-cell biology.
- **Current evidence:** FCER1A, CD1C, CD1E, FLT3, KLRB1, JCHAIN, STAT5A, and STAT5B show coordinated protective associations.
- **External support or conflict:** Tissue-expression and disease annotations make immune-cell localization plausible, but the evidence pack does not provide matched single-cell, spatial, or deconvolution estimates. No external survival replication was supplied.
- **Next step:** Apply validated bulk-RNA deconvolution, compare with tumor purity and pathology-based immune scores, and use multiplex immunohistochemistry or spatial transcriptomics to localize the transcripts. Refit survival models after adjustment for immune abundance.
- **Conclusion status:** **Supported hypothesis regarding composition**, but the claim of an intrinsically protective immune mechanism is **insufficient evidence**.

### 4. AURKA/TPX2/PLK1-centered network as a therapeutic vulnerability  
**Classification:** Therapeutic target

- **Why prioritize it:** The dataset identifies a coherent mitotic network associated with poor OS, making it a rational experimental vulnerability to test.
- **Current evidence:** AURKA, TPX2, KIF4A, NUSAP1, PRC1, CDC20, and related genes are risk-associated and appear in STRING network records.
- **External support or conflict:** Network and pathway records support mechanistic plausibility, and therapeutic records exist for some genes in the broader evidence pack. However, drug availability is not evidence of efficacy, and no treatment-response or functional breast-cancer experiment was supplied.
- **Next step:** Test dependency and response in breast-cancer models stratified by the mitotic signature, using genetic perturbation and pharmacologic inhibition with rescue experiments; evaluate normal-cell toxicity and subtype-specific effects.
- **Conclusion status:** **Exploratory hypothesis**, not an established therapeutic target.

### 5. LARP1/STIP1/GSK3B growth-regulatory axis  
**Classification:** Interaction / network hypothesis

- **Why prioritize it:** LARP1, STIP1, and GSK3B are among the strongest risk-associated genes and could represent a tumor-growth/stress program distinct from simple mitotic activity.
- **Current evidence:** LARP1 **HR=1.2611983**, STIP1 **HR=1.2368966**, and GSK3B **HR=1.2271421**, all with FDR below **1.2×10⁻9**. GSK3B has database-supported associations with Wnt-related proteins and cell-cycle signaling.
- **External support or conflict:** The supplied literature record links STIP1 with prognosis and immune infiltration in pan-cancer analysis (PMID **37488801**). This supports plausibility but is not breast-cancer cohort replication. No direct physical interaction among LARP1, STIP1, and GSK3B is supplied.
- **Next step:** Determine whether the genes remain prognostic after adjustment for proliferation, measure pathway activity at RNA and protein levels, and test pairwise perturbations for epistasis in breast-cancer models.
- **Conclusion status:** **Exploratory hypothesis**.

## 5. Major limitations and alternative explanations

1. **No independent statistical validation:** Pathway recurrence, STRING records, tissue annotations, and literature are not replication. A second cohort with OS HRs, confidence intervals, P values, and FDRs is required.
2. **Potential statistical or technical inflation:** The fact that all 100 genes are significant, together with six duplicated rows and tightly clustered HRs, warrants inspection of sample size, event count, proportional-hazards assumptions, normalization, probe mapping, batch effects, and whether genes were preselected using the same survival outcome.
3. **Tumor purity and cellular composition:** Protective immune and stromal genes may primarily report infiltrating cells, while epithelial genes may report tumor content. Deconvolution, pathology review, single-cell or spatial profiling, and purity-adjusted survival models are appropriate.
4. **Clinical and molecular confounding:** Stage, grade, age, treatment, molecular subtype, receptor status, and metastatic burden can drive both gene expression and OS. Multivariable and stratified analyses are needed.
5. **Association is not causation:** A risk-associated gene may be a passenger or marker of aggressive biology, and a protective-associated gene may mark a favorable microenvironment without directly improving survival. Functional perturbation and prospective biomarker validation are required.

Overall, the most defensible interpretation is a strong within-cohort association between poor OS and a broad mitotic/proliferative program, accompanied by protective-associated immune and stromal signatures; the mechanistic and translational implications remain hypotheses until validated in independent cohorts and experimentally localized.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=71, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
